Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases afterremnant gastric cancer resection

World Journal of Gastroenterology

Volumn 13, Issue 45, 2007, Pages 6115-6118

  Sun, Long ^a   Ye, Huang Yang ^a   Zhang, Ying Hong ^a   Guan, Yong Song ^b   Wu, Hua ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

18F fluorodeoxyglucose; Cetuximab; Hepatic metastasis; Positron emission tomography computer tomography; Recombinant human endostatin; Remnant gastric cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; ENDOSTAR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUORODEOXYGLUCOSE F 18; RECOMBINANT HUMAN ENDOSTATIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GASTRECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER METASTASIS; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; SKIN TOXICITY; STOMACH CANCER; TREATMENT RESPONSE;

EID: 36949006090     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.13.6115     Document Type: Article

References (15)

1. Shelton JG, Steelman I.S, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets 2005; 9:1009-1030
2. FDA approves Erbitux (cetuximab) to treat patients with advanced colorectal cancer. http://www.fda.gov/cder/drug/infopage/erbitux/ default.htm
3. SFDA approves recombinant human endostatin (Endostar) to treat patients with cancer.http://appl.sfda.gov.cn/webportal/ portal.po?UID=DWV1_WOUID_URL_11635827 &POpType=DBSearch&DBSearch=DJSearch&DJSearch=DJ DetailPg&DJDetailPg=MTcyNTEx&selDbName=PLDB_TB L_TABLE7&tbICol=OID&Ptype1_sld=O&Ptype2_sld=O&Pty pe3_sld=O
4. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007;5: 203-220
5. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Mehsi D, De Vita F, De Placido S, Bianco AR, Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10: 784-793
6. Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 2006;12:3297-3305
7. Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003;1: 438-445
8. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005;8: 155-163
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsern E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
10. Wang JW, Sun Y, Liu YY, Yu QT, Zhang YP, Li K, Zhu YZ, Zhou QH, Hou M, Guan ZZ, Li WL, Zhuang W, Wang DL, Liang HJ, Qin FZ, Lu HS, Liu XQ Sun H, Zhang YJ, Wang JJ, Luo SX, Yang RH, Tu YR, Wang XW, Song SP, Zhou JM, You LF, Wang J, Yao C. Results of randon-tized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Feiai Zazhi 2005;4: 283-290
11. Weissleder R. Molecular imaging in cancer. Science 2006; 312: 1168-1171
12. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007; 244: 39-47
13. Shu CJ, Guo S, Kim Yj, Shelly SM, Nijagal A, Ray P, Gambhir SS, Radu CG, Witte ON. Visualization of a primary anti-tumor immune response by positron en-dssion tomography. Proc Natl Acad Sci USA 2005; 102:17412-17417
14. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-1143
15. Gillies RJ. Noninvasive imaging of anticancer therapy. Mol Cancer Ther 2003;2: 333-334